Clinical Trials Logo

Filter by:
NCT ID: NCT04611997 Active, not recruiting - Gastric Cancer Clinical Trials

IGG Using in Laparoscopic Gastrectomy for Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy

Start date: November 16, 2020
Phase: Phase 3
Study type: Interventional

Patients with locally advanced gastric adenocarcinoma (cT2-4a N-/+ M0) were selected as study subjects to investigate the safety, efficacy, and feasibility of ICG near-infrared imaging tracing in guiding laparoscopic D2 lymph node dissection for gastric cancer after neoadjuvant chemotherapy by comparing injection ICG group and non-injection ICG group

NCT ID: NCT04609631 Active, not recruiting - Depression Clinical Trials

Tai Chi for Comorbid Depression in T2DM Patients

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

Previous studies suggested that Tai Chi may be beneficial for T2DM patients. However, no studies have investigated the effectiveness of Tai Chi for comorbid depression in T2DM patients, as well as the optimal frequency of Tai Chi. Thus, we intend to investigate the effectiveness of Tai Chi for comorbid depression in T2DM patients and test whether the effectiveness of Tai Chi depends on its frequency.

NCT ID: NCT04606680 Active, not recruiting - Obesity Clinical Trials

Herb-partitioned Moxibustion Plus Lifestyle Modification Treatment for Simple Obesity

Start date: April 30, 2019
Phase: N/A
Study type: Interventional

This study is designed as a three-dummy randomised controlled trial to evaluate the efficacy and safety of herb-partitioned moxibustion plus lifestyle modification treatment in patients with simple obesity.

NCT ID: NCT04605796 Active, not recruiting - Clinical trials for Advanced Hepatocellular Carcinoma (HCC)

A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)

Start date: April 10, 2020
Phase: Phase 2
Study type: Interventional

This is an open-label, single-arm, national multicenter phase II clinical study to preliminarily observe and evaluate the efficacy and safety of Toripalimab combined with Bevacizumab as the first-line therapy for advanced HCC The study will use safety/tolerability and ORR as the primary study objectives and indicators, and plans to enroll about 50-60 patients.

NCT ID: NCT04605185 Active, not recruiting - Clinical trials for Unresectable Hepatocellular Carcinoma

Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma

Start date: January 8, 2021
Phase: Phase 1
Study type: Interventional

This study is the single-center, open-label phase I clinical trial to evaluate tolerability, safety and efficacy of Donafenib and JS001 in combination with TCAE in patients with Unresectable Hepatocellular Carcinoma.

NCT ID: NCT04603846 Active, not recruiting - Clinical trials for Advanced Urothelial Carcinoma

A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial Carcinoma

Start date: September 10, 2020
Phase: Phase 1
Study type: Interventional

To evaluate the safety and efficacy of recombinant anti-PD-L1 monoclonal antibody injection (ZKAB001) combined with Albumin-bound paclitaxel in the treatment of Advanced urothelial carcinoma

NCT ID: NCT04601935 Active, not recruiting - Clinical trials for Relapsed/Refractory Multiple Myeloma

A Single-center Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of a BCMA-targeted Universal LCAR-BCX Cells in Patients With Relapsed/Refractory Multiple Myeloma

Start date: October 9, 2020
Phase: Phase 1
Study type: Interventional

This is a prospective, single-arm, single-center, open-label dose-finding and dose-expansion study that evaluates the safety, tolerability, PK, and anti-tumor efficacy of LCAR-BCX cells in subjects with relapsed/refractory multiple myeloma

NCT ID: NCT04600817 Active, not recruiting - Clinical trials for Newly Diagnosed Glioblastoma

A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)

Start date: December 31, 2020
Phase: Phase 2
Study type: Interventional

A Phase 2, Randomized, Single-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients with Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)

NCT ID: NCT04600219 Active, not recruiting - Clinical trials for Hemodialysis Complication

The Effect of Tyrosine Kinase Receptor Axl on Dialysis Prognosis in Chronic Hemodialysis Patients

Start date: January 1, 2018
Phase:
Study type: Observational

The purpose of this study is to evaluate whether tyrosine kinase receptor Axl affects the dialysis prognosis in chronic hemodialysis patients

NCT ID: NCT04597541 Active, not recruiting - Solid Tumor, Adult Clinical Trials

A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors

Start date: October 21, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of AK112, a PD-1/VEGF bispecific antibody, as a single agent in adult subjects with advanced solid tumor malignancies. This trial is a two parts, phase I/II study. All patients are advanced solid tumor, Eastern Cooperative Oncology Group (ECOG) performance status 0-1. Part one is dose escalation phase,part two is dose expansion phase. The primary end point is safety. Secondary end points are objective response rate,progression-free survival and overall survival per RECIST1.1.